Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare Biotechnology

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.

GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger) > Looks like Dan never fails to disappoint

<< Previous

Bullboard Posts

Next >>

Comment by 3burtcon Jan 11, 2021 8:56am

182 Views

Post# 32265671

RE:RE:RE:Looks like Dan never fails to disappoint

Ya oh no, oh my god what I do now. Say it isn't so. Phase 3 didn't start yet, what a surprise. Look out the sky is starting to fall. Oh update didnt happen Friday, monday terrible. 1 = 10 alias. Listening to these week bashers won't benefit you. Oh no dilution, look out it was a reverse split. Scary bashers who bash, bash, bash, but no way in hell will they sell!

<< Previous

Bullboard Posts

Next >>

Showcase Minerals identifies uranium and rare earth elements in Quebec